Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer

Biomaterials

Volumn 101, Issue , 2016, Pages 20-31

  Brinkman, Ashley M ^a,b   Chen, Guojun ^b,c   Wang, Yidan ^a   Hedman, Curtis J ^d   Sherer, Nathan M ^a   Havighurst, Thomas C ^e   Gong, Shaoqin ^b,c   Xu, Wei ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c Wisconsin Electric Machines and Power Electronics Consortium   (United States)

^d WISCONSIN STATE LABORATORY OF HYGIENE   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Aminoflavone; GE11; Targeted drug delivery; Triple negative breast cancer; Unimolecular micelle nanoparticles

Indexed keywords

ENZYME INHIBITION; MICELLES; NANOPARTICLES; PEPTIDES; TUMORS;

AMINOFLAVONE; GE11; TARGETED DRUG DELIVERY; TRIPLE-NEGATIVE BREAST CANCERS; UNIMOLECULAR MICELLES;

DISEASES;

AMINOFLAVONE; ASPARTATE AMINOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLAVONE DERIVATIVE; NANOPARTICLE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; UNIMOLECULAR MICELLE NANOPARTICLE; ANTINEOPLASTIC AGENT; DRUG CARRIER; FLAVONOID; GE11 PEPTIDE; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PH; CANCER INHIBITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG TARGETING; DRUG TUMOR LEVEL; ENDOSOME; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NANOENCAPSULATION; NANOFORMULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THERAPEUTIC INDEX; TISSUE INJURY; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR XENOGRAFT; BREAST; CHEMISTRY; DRUG EFFECTS; FEMALE; METABOLISM; MICELLE; PATHOLOGY; TUMOR CELL LINE; ULTRASTRUCTURE;

ANTINEOPLASTIC AGENTS; BREAST; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; FLAVONOIDS; HUMANS; MICELLES; NANOPARTICLES; PEPTIDES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84971377528     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.05.041     Document Type: Article

References (49)

1. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 2007, 13:4429-4434.
2. Liedtke C., Mazouni C., Hess K.R., André F., Tordai A., Mejia J.A., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2008, 26:1275-1281.
3. Carey L.A. Directed therapy of subtypes of triple-negative breast cancer. Oncologist 2011, 16(Suppl. 1):71-78.
4. Mancini P., Angeloni A., Risi E., Orsi E., Mezi S. Standard of care and promising new agents for triple negative metastatic breast cancer. Cancers (Basel) 2014, 6:2187-2223.
5. Moran M.S. Radiation therapy in the locoregional treatment of triple-negative breast cancer. Lancet Oncol. 2015, 16:e113-e122.
6. Berry D.A., Cirrincione C., Henderson I.C., Citron M.L., Budman D.R., Goldstein L.J., et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006, 295:1658-1667.
7. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore D.T., Collichio F., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 2007, 13:2329-2334.
8. McLean L., Soto U., Agama K., Francis J., Jimenez R., Pommier Y., et al. Aminoflavone induces oxidative DNA damage and reactive oxidative species-mediated apoptosis in breast cancer cells. Int. J. Cancer 2008, 122:1665-1674.
9. Brinkman A.M., Wu J., Ersland K., Xu W. Estrogen receptor α and aryl hydrocarbon receptor independent growth inhibitory effects of aminoflavone in breast cancer cells. BMC Cancer 2014, 14:344.
10. Meng L.H., Kohlhagen G., Liao Z.Y., Antony S., Sausville E., Pommier Y. DNA-protein cross-links and replication-dependent histone H2AX phosphorylation induced by aminoflavone (NSC 686288), a novel anticancer agent active against human breast cancer cells. Cancer Res. 2005, 65:5337-5343.
11. Meng L.H., Meng Z., Miao Z.H., Veenstra T.D., Pommier Y. Cytokeratin-RNA cross-linking mediated by the antitumor aminoflavone, 5-amino-2,3-fluorophenyl-6,8-difluoro-7-methyl-4H-1-benzopyran-4-one. J. Pharmacol. Exp. Ther. 2008, 325:674-680.
12. Meng L.H., Kohn K.W., Pommier Y. Dose-response transition from cell cycle arrest to apoptosis with selective degradation of Mdm2 and p21WAF1/CIP1 in response to the novel anticancer agent, aminoflavone (NSC 686,288). Oncogene 2007, 26:4806-4816.
13. Loaiza-Pérez A.I., Kenney S., Boswell J., Hollingshead M., Hose C., Linehan W.M., et al. Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1. J. Urol. 2004, 171:1688-1697.
14. NIH DCTD. Aminoflavone Toxicology Summary. http://dctd.cancer.gov/FeaturedAgents/pdfs/710464AminoflavoneToxAbstract.pdf.
15. Grossi I.M., Lynch M., Merrill J.W., Covey J.M., Tomaszewski J.E., Peggins J.O. Pulmonary function effects of a three-hour infusion of aminoflavone prodrug (NSC-694501) in dogs. Toxicol. March 2004, 73. Abstract Number: 686.
16. Reeder-Hayes K.E., Carey L.A., Sikov W.M. Clinical trials in triple negative breast cancer. Breast Dis. 2010, 32:123-136.
17. Reis-Filho J.S., Pinheiro C., Lambros M.B., Milanezi F., Carvalho S., Savage K., et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J. Pathol. 2006, 209:445-453.
18. Gumuskaya B., Alper M., Hucumenoglu S., Altundag K., Uner A., Guler G. EGFR expression and gene copy number in triple-negative breast carcinoma. Cancer Genet. Cytogenet 2010, 203:222-229.
19. Abourbeh G., Shir A., Mishani E., Ogris M., Rödl W., Wagner E., et al. PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors. IUBMB Life 2012, 64:324-330.
20. Li Z., Zhao R., Wu X., Sun Y., Yao M., Li J., et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2005, 19:1978-1985.
21. Torchilin V.P. Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 2006, 58:1532-1555.
22. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
23. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 2007, 24:1-16.
24. Xiao Y., Hong H., Javadi A., Engle J.W., Xu W., Yang Y., et al. Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials 2012, 33:3071-3082.
25. Xiao L., Xiong X., Sun X., Zhu Y., Yang H., Chen H., et al. Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles. Biomaterials 2011, 32:5148-5157.
26. Nishiyama N., Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol. Ther. 2006, 112:630-648.
27. Jaskula-Sztul R., Xu W., Chen G., Harrison A., Dammalapati A., Nair R., et al. Thailandepsin A-loaded and octreotide-functionalized unimolecular micelles for targeted neuroendocrine cancer therapy. Biomaterials 2016, 91:1-10.
28. Prabaharan M., Grailer J.J., Pilla S., Steeber D.A., Gong S. Folate-conjugated amphiphilic hyperbranched block copolymers based on Boltorn H40, poly(L-lactide) and poly(ethylene glycol) for tumor-targeted drug delivery. Biomaterials 2009, 30:3009-3019.
29. Xiao Y., Hong H., Javadi A., Engle J.W., Xu W., Yang Y., et al. Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials 2012, 33:3071-3082.
30. Guo J., Hong H., Chen G., Shi S., Zheng Q., Zhang Y., et al. Image-guided and tumor-targeted drug delivery with radiolabeled unimolecular micelles. Biomaterials 2013, 34:8323-8332.
31. Chen G., Wang L., Cordie T., Vokoun C., Eliceiri K.W., Gong S. Multi-functional self-fluorescent unimolecular micelles for tumor-targeted drug delivery and bioimaging. Biomaterials 2015, 47:41-50.
32. Zhou Y., Huang W., Liu J., Zhu X., Yan D. Self-assembly of hyperbranched polymers and its biomedical applications. Adv. Mater. 2010, 22:4567-4590.
33. Calderon M., Quadir M.A., Sharma S.K., Haag R. Dendritic polyglycerols for biomedical applications. Adv. Mater. 2010, 22:190-218.
34. Chen G., Jaskula-Sztul R., Harrison A., Dammalapati A., Xu W., Cheng Y., et al. KE108-conjugated unimolecular micelles loaded with a novel HDAC inhibitor thailandepsin-a for targeted neuroendocrine cancer therapy. Biomaterials 2016, 97:22-33.
35. Tomayko M.M., Reynolds C.P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 1989, 24:148-154.
36. Wiegand R., Wu J., Sha X., LoRusso P., Heath E., Li J. Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate aminoflavone (NSC 686288) in human plasma. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2009, 877:1460-1464.
37. Lee J.S., Ankone M., Pieters E., Schiffelers R.M., Hennink W.E., Feijen J. Circulation kinetics and biodistribution of dual-labeled polymersomes with modulated surface charge in tumor-bearing mice: comparison with stealth liposomes. J. Control Release 2011, 155:282-288.
38. Tomao F., Papa A., Zaccarelli E., Rossi L., Caruso D., Minozzi M., et al. Triple-negative breast cancer: new perspectives for targeted therapies. Onco Targets Ther. 2015, 8:177-193.
39. Sutton L.M., Han J.S., Molberg K.H., Sarode V.R., Cao D., Rakheja D., et al. Intratumoral expression level of epidermal growth factor receptor and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma. Am. J. Clin. Pathol. 2010, 134:782-787.
40. Zhai J., Scoble J.A., Li N., Lovrecz G., Waddington L.J., Tran N., et al. Epidermal growth factor receptor-targeted lipid nanoparticles retain self-assembled nanostructures and provide high specificity. Nanoscale 2015, 7:2905-2913.
41. Nascimento A.V., Singh A., Bousbaa H., Ferreira D., Sarmento B., Amiji M.M. Mad2 checkpoint gene silencing using epidermal growth factor receptor-targeted chitosan nanoparticles in non-small cell lung cancer model. Mol. Pharm. 2014, 11:3515-3527.
42. Wang Y., Zhou J., Qiu L., Wang X., Chen L., Liu T., et al. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells. Biomaterials 2014, 35:4297-4309.
43. Ren H., Zhou L., Liu M., Lu W., Gao C. Peptide GE11-polyethylene glycol-polyethylenimine for targeted gene delivery in laryngeal cancer. Med. Oncol. 2015, 32:624.
44. Johnson R., Sabnis N., McConathy W.J., Lacko A.G. The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer. Pharmaceutics 2013, 5:353-370.
45. Sykes E.A., Chen J., Zheng G., Chan W.C. Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. ACS Nano 2014, 8:5696-5706.
46. Toporkiewicz M., Meissner J., Matusewicz L., Czogalla A., Sikorski A.F. Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges. Int. J. Nanomed. 2015, 10:1399-1414.
47. Malam Y., Loizidou M., Seifalian A.M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 2009, 30:592-599.
48. Bazley L.A., Gullick W.J. The epidermal growth factor receptor family. Endocr. Relat. Cancer 2005, 12(Suppl. 1):S17-S27.
49. Shin G., Kang T.-W., Yang S., Baek S.-J., Jeong Y.-S., Kim S.-Y. GENT: gene expression database of normal and tumor tissues. Cancer Inf. 2011, 10:149.